Compare Essex Property Trust, Inc. (ESS) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Essex Property Trust, Inc. vs Novavax Inc — how do they compare? Essex Property Trust, Inc. trades at $297.75 (market cap $18.82B), while Novavax Inc trades at $8.22 (market cap $1.39B). The key difference: Essex Property Trust, Inc. is far larger — about 13.5× Novavax Inc's market cap, and Essex Property Trust, Inc. pays a 3.54% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| ESS | NVAX | |
|---|---|---|
Market Cap | $18.82B | $1.39B |
Sector | Real Estate | Health |
52-Week High | $298.33 | $11.19 |
52-Week Low | $239.61 | $6.22 |
Enterprise Value | $25.54B | $890.94M |
Dividend Yield | 3.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ESS trades at $297.29, down slightly by 0.28% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 results expected soon. Fundamentals show robust profitability with a 30.03% net income margin and $669.67M net income for 2025, though valuation ratios like a P/E of 32.93 appear elevated. Recent news highlights sustainability initiatives and inclusion in the Russell Microcap Index.
The outlook for ESS is cautiously optimistic, supported by high West Coast rental demand and AI-driven employment growth. Risks include elevated debt levels and Seattle market weakness. Analysts are mixed with a $294.25 consensus price target, slightly below the current price, suggesting limited near-term upside amid solid operational performance.
Novavax (NVAX) trades at $8.21, down 2.49% amid bearish technical signals and negative cash flow trends. The company shows mixed fundamentals with strong revenue growth to $1.12B in 2025 and three consecutive earnings beats, but faces profitability challenges with negative net income margin and ROE. Recent news highlights shareholder dissent and underperformance versus broader market trends, while analyst consensus remains bullish with a $14 price target representing 70% upside potential.
The outlook balances significant upside potential against substantial execution risks. Positive catalysts include consistent earnings beats and strong analyst support, but concerns persist around cash burn, negative equity, and competitive vaccine market pressures. Investors face volatility from operational challenges despite attractive valuation multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Essex Property Trust, Inc.
Essex Property Trust owns a portfolio of 253 apartment communities with over 62,000 units and is developing three additional properties with 571 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
Read more on ESS →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
